Turbanti L, Cerbai G, Di Bugno C, Giorgi R, Garzelli G, Criscuoli M, Renzetti A R, Subissi A, Bramanti G, DePriest S A
Laboratori Guidotti S.p.A., Pisa, Italy.
J Med Chem. 1993 Mar 19;36(6):699-707. doi: 10.1021/jm00058a006.
A series of monoamidic derivatives of cis- and trans-1,2-cyclohexanedicarboxylic and 1,2-cyclopentanedicarboxylic acids bearing either a carboxylic, sulfhydrylic, or hydroxamic group in the side chain were synthesized and evaluated in vitro for their inhibitory activity against angiotensin converting enzyme. The compounds were designed as potential ACE inhibitors of novel structure, assuming that a monoamidic residue of an 1,2-cyclomethylenedicarboxylic acid could be an alternative structure to the acylproline moiety, the carboxyl-terminal portion common to various ACE inhibitors. The most active compounds were found in the hydroxamic derivatives of cyclohexane series; within this series of derivatives a marked increase of potency was caused by alkylation of the amidic nitrogen with a methyl or ethyl group. Therefore enantiomers of the selected hydroxamic derivatives of cis- and trans-1,2-cyclohexanedicarboxylic acid were prepared by two different chiral synthetic routes and evaluated in vitro for their ACE inhibitor potencies. The active enantiomers both of the cis series (21a, 21c) and trans series (16b, 16d) were found to have all R configuration at the C-2 and R or S configuration at the C-1, while in the classical ACE inhibitors S configuration at the terminal carboxylate (corresponding to the C-1 of our compounds) is strictly required for activity. The most potent compound of the series was (1S,2R)-cis-2[[[2-(hydroxyamino)-2-oxoethyl]methylamino]carbonyl] cyclohexanecarboxylic acid (21a) with an IC50 value of 7.0 nM compared with the value of 3.0 nM for captopril. Further 21a was shown to be highly selective and competitive ACE inhibitor. These results indicate that this non-amino acid structure of inhibitors meets the ACE active site requirements for the binding. The binding compatibility of the most active compounds with a model of ACE active site was evaluated by molecular modeling techniques.
合成了一系列顺式和反式-1,2-环己烷二甲酸及1,2-环戊烷二甲酸的单酰胺衍生物,其侧链带有羧基、巯基或异羟肟酸基团,并在体外评估了它们对血管紧张素转换酶的抑制活性。这些化合物被设计为新型结构的潜在ACE抑制剂,假定1,2-环亚甲基二甲酸的单酰胺残基可以作为酰基脯氨酸部分的替代结构,酰基脯氨酸部分是各种ACE抑制剂共有的羧基末端部分。在环己烷系列的异羟肟酸衍生物中发现了最具活性的化合物;在该系列衍生物中,酰胺氮用甲基或乙基烷基化导致活性显著增加。因此,通过两种不同的手性合成路线制备了顺式和反式-1,2-环己烷二甲酸所选异羟肟酸衍生物的对映体,并在体外评估了它们的ACE抑制活性。发现顺式系列(21a,21c)和反式系列(16b,16d)的活性对映体在C-2处均具有全R构型,在C-1处具有R或S构型,而在经典的ACE抑制剂中,末端羧酸盐处的S构型(对应于我们化合物的C-1)是活性严格要求的。该系列中最有效的化合物是(1S,2R)-顺式-2[[[2-(羟基氨基)-2-氧代乙基]甲基氨基]羰基]环己烷羧酸(21a),IC50值为7.0 nM,而卡托普利的值为3.0 nM。此外,21a被证明是一种高度选择性和竞争性的ACE抑制剂。这些结果表明,这种抑制剂的非氨基酸结构符合ACE活性位点的结合要求。通过分子建模技术评估了最具活性的化合物与ACE活性位点模型的结合相容性。